NVCR stock. NovoCure’s business case stays in view.
This article discusses NovoCure Ltd. (NVCR), a cancer care company known for its tumor treating fields platform, including its flagship product Optune. It highlights the company's business model, particularly its focus on recurring adoption, reimbursement, and physician familiarity, rather than short-term product cycles. The piece emphasizes the importance of the Nasdaq listing for U.S. investors and positions NovoCure as a small-cap healthcare company driven by product uptake and clinical evidence.
Is NovoCure (NVCR) Cheap As TRIDENT Fallout Clouds Its Valuation?
NovoCure (NVCR) is under scrutiny after a legal investigation into potential claims related to its Phase 3 TRIDENT trial results, which caused a sharp stock price drop. While the company has seen recent momentum, its long-term performance is weak, and its valuation is clouded by the TRIDENT fallout. Analysts consider it 34% undervalued, with a fair value of $26.07, suggesting potential for growth if new indications are approved and adopted, but this is tempered by risks like stalled prescription growth or slow reimbursement.
NovoCure (NVCR) CHRO acquires 1,905 discounted shares in ESPP purchase
NovoCure Ltd.'s Chief Human Resources Officer, Michal Nath Puri, acquired 1,905 ordinary shares through the company's 2025 Employee Share Purchase Plan on June 30, 2026. The shares were purchased at a discounted price of $11.15 each, representing 85% of the closing price on January 1, 2026. This transaction increased Puri's direct holdings to 203,227 ordinary shares and is exempt under Rule 16b-3(c) as a routine compensation-related acquisition.
NovoCure's Cancer Treatment Device Option Pax Gets European Approval
NovoCure Limited has received CE mark approval for its portable medical device, Option Pax, to treat locally advanced pancreatic cancer in Europe. This treatment, used concomitantly with gemcitabine and nab-paclitaxel, had previously received FDA approval and will be launched in Germany first. The approval is based on positive results from the Phase III PANOVA-3 study, which showed a statistically significant improvement in overall survival and time to pain progression.
Novocure to Report Second Quarter 2026 Financial Results
Novocure (NASDAQ: NVCR) is set to announce its financial results for the second quarter of 2026 on July 23, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss these results. Novocure, a global oncology company, focuses on extending survival for aggressive cancers through its Tumor Treating Fields therapy.
NovoCure (NVCR) General Counsel adds 1,299 ESPP shares to holdings
NovoCure Ltd's General Counsel, Ben Arye Barak, acquired 1,299 ordinary shares through the company's 2025 Employee Share Purchase Plan (ESPP) for the period of January 1, 2026, through June 30, 2026. The shares were purchased at a reported price of $11.15 each, bringing his direct holdings to 243,752 shares. This transaction, which is exempt under Rule 16b-3(c), was based on 85% of the January 1, 2026 closing price.
NovoCure (NVCR) CEO adds 1,905 shares through 2025 employee share purchase plan
NovoCure's CEO, Leonard Frank X, acquired 1,905 ordinary shares at $11.15 each through the company's 2025 Employee Share Purchase Plan for the first half of 2026. This transaction is exempt under Rule 16b-3(c) and increases his direct holdings to 461,425 ordinary shares. The purchase price represents 85% of the closing price on January 1, 2026, as per the ESPP terms.
NovoCure (NASDAQ: NVCR) director adds shares through 2025 employee stock purchase plan
NovoCure Ltd director Asaf Danziger acquired 268 ordinary shares through the company's 2025 Employee Share Purchase Plan (ESPP) at $11.15 per share. This routine, compensation-related transaction, exempt under Rule 16b-3(c), increased Danziger's direct holdings to 416,742 ordinary shares. The purchase price was set at 85% of NovoCure's closing price on January 1, 2026, for the ESPP period from January 1, 2026, through June 30, 2026.
Novocure sets July 23 call for Q2 2026 results before markets open
Novocure (NASDAQ: NVCR) will report its second quarter 2026 financial results on July 23, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss these results. Novocure is an oncology company specializing in Tumor Treating Fields therapy for aggressive cancers.
NVCR - NovoCure Ltd Volatility & Greeks
This article provides a detailed financial overview of NovoCure Ltd (NVCR), including its stock performance, key financial metrics, and volatility. It highlights the company's market capitalization, income, sales, and various financial ratios, alongside insider ownership and institutional transactions. The data also covers its recent stock changes, volume, and performance over different periods.
Novocure receives CE Mark for pancreatic cancer device in Europe
Novocure's Optune Pax device has received CE Mark approval in Europe for treating locally advanced pancreatic cancer when used with chemotherapy. This approval is based on Phase 3 trial results showing improved overall survival and time to pain progression for patients using Optune Pax. The company plans to launch the device in Germany soon, targeting a significant unmet medical need in Europe where pancreatic cancer is a leading cause of cancer death.
Novocure wins CE Mark for Optune Pax pancreatic cancer treatment
Novocure's Optune Pax device has received CE Mark approval for treating locally advanced pancreatic cancer in Europe, following prior U.S. approval. The approval is based on Phase 3 PANOVA-3 trial results showing a 2-month median overall survival benefit and improved quality of life compared to chemotherapy alone. The company plans to launch the device in Germany soon.
Wearable pancreatic cancer device Optune Pax wins CE Mark in Europe
Novocure's wearable medical device, Optune Pax, has received CE Mark approval for treating locally advanced pancreatic cancer in Europe. This approval is based on data from the Phase 3 PANOVA-3 trial, which showed a statistically significant improvement in overall survival and delayed pain progression when Optune Pax was used with chemotherapy. The company plans to launch Optune Pax in Germany soon, offering a new treatment option for this aggressive cancer.
Optune Pax CE Mark expands Novocure (NASDAQ: NVCR) pancreatic cancer reach
Novocure's wearable device, Optune Pax, has received CE Mark approval for treating locally advanced pancreatic cancer in adults when used with gemcitabine and nab-paclitaxel. This approval is supported by positive Phase 3 PANOVA-3 trial data, which showed significant improvements in overall survival and time to pain progression, with manageable safety. Novocure plans to launch Optune Pax in Germany soon and continue efforts to secure access across Europe.
NovoCure (NVCR) Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields Start
NovoCure's stock rose 8.1% after its Phase 3 TRIDENT trial revealed no significant survival benefit from starting Tumor Treating Fields (TTFields) earlier for glioblastoma patients. The results indicate that the timing of TTFields initiation, rather than the therapy's feasibility, is key for integration into GBM care. Despite this, the company's core GBM franchise and approval for pancreatic cancer treatment remain important for its growth narrative, with analysts forecasting substantial revenue and earnings by 2029.
NovoCure (NVCR) Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields Start
NovoCure (NVCR) shares rose 8.1% after its Phase 3 TRIDENT trial revealed that starting Tumor Treating Fields (TTFields) earlier with chemoradiation did not improve overall survival in glioblastoma patients compared to starting later. While the timing of TTFields application for glioblastoma did not yield additional survival benefits from an earlier start, the core investment thesis for NovoCure, relying on TTFields expansion into new cancers, remains largely intact, buoyed by the recent FDA approval of Optune Pax for pancreatic cancer. The company's future growth depends on the successful adoption and reimbursement of new indications to offset any negative sentiment from the TRIDENT results.
NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh
This article provides an overview of NovoCure Ltd. (N2VC34) stock, focusing on its actuals and estimates. It highlights financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics for both annual and quarterly periods. The content emphasizes comparing actual results with average, high, and low estimates, alongside visualizing trends.
NovoCure (NVCR) Could Be 42% Undervalued On Mixed TRIDENT Trial Results
NovoCure (NVCR) is considered potentially 42% undervalued despite reporting mixed topline Phase 3 TRIDENT data for glioblastoma that showed no statistically significant overall survival benefit. The stock's current price of US$15.05 is a significant discount to its estimated fair value of $26.07, driven by potential future regulatory approvals and market expansion for its TTFields therapy. Investors are advised to review the company's financial data and risks, as the narrative highlights both potential growth from new indications and challenges from adoption and reimbursement.
NVCR Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for NovoCure Limited (NVCR) stock, based on analysis from several financial experts. It details the current stock price, historical performance, and analysts' maximum and minimum price estimates for the company. Additionally, the article covers financial metrics such as market capitalization, upcoming earnings reports, past earnings, revenue, net income, and EBITDA, along with information on volatility and dividend policy.
NovoCure Ltd. Actuals & Estimates (NASDAQ:NVCR)
This article provides an overview of NovoCure Limited (NASDAQ: NVCR) stock, including current price, historical performance, analyst forecasts, and detailed financial data. It covers earnings, revenue, market capitalization, EBITDA, and upcoming earnings report dates. The article also touches on investment advice disclaimers and basic stock trading information.
NovoCure Ltd. Actuals & Estimates (LSX:A140ML)
This article provides comprehensive financial data and analyst estimates for NovoCure Ltd. (A140ML) on the Lang & Schwarz Exchange. It covers the company's stock performance, market capitalization, earnings, revenue, and future price forecasts, alongside frequently asked questions about its stock. The data indicates recent volatility and projected earnings for upcoming quarters.
NovoCure (NVCR) Could Be 42% Undervalued On Mixed TRIDENT Trial Results
NovoCure (NVCR) stock is under scrutiny after its Phase 3 TRIDENT trial data for glioblastoma showed no statistically significant overall survival benefit. Despite recent share price volatility, the stock is considered by some narratives to be 42.3% undervalued at $15.05 against a fair value of $26.07, anticipating future growth from new indications and market expansion. Investors are urged to review the financial details and risks given the mixed reports and potential for rapid change.
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $46
H.C. Wainwright has reiterated its Buy rating for Novocure (NVCR.US) and maintained a target price of $46. This indicates continued confidence from the firm in the company's stock performance and future prospects.
NovoCure (NVCR) Is Down 19.7% After TRIDENT Misses Survival Endpoint In Earlier TTFields Use
NovoCure's stock fell 19.7% after its Phase 3 TRIDENT trial, testing earlier use of Tumor Treating Fields (TTFields) for glioblastoma, missed its primary endpoint of improving overall survival. While this is a setback for earlier GBM use, the company's broader investment narrative now focuses more on expanding TTFields into new cancer types like pancreatic cancer, following a recent FDA approval. Investors should consider how this data impacts future revenue expectations and the company's dependency on a single platform amidst ongoing losses.
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
SueWallSt has initiated an investigation into the officers and directors of Novocure Limited (NVCR) following a significant 18% stock drop on June 18, 2026. This decline occurred after the company's Phase 3 TRIDENT trial, testing a new glioblastoma treatment approach, failed to meet its primary endpoint of increased overall survival. Investors who suffered losses are encouraged to contact SueWallSt for a free evaluation of their potential legal rights.
NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result
NovoCure (NVCR) shares are reacting to topline data from its Phase 3 TRIDENT trial, showing no improvement in overall survival when starting Tumor Treating Fields therapy during chemoradiation. While the stock has seen recent momentum, with a 36.1% year-to-date increase, one valuation narrative suggests it is 31.5% undervalued at $17.85, with a fair value of $26.07. Another valuation method, the Simply Wall St DCF model, estimates a much higher value of $172.49, implying an 89.7% undervaluation.
NovoCure (NVCR) Is Down 19.7% After TRIDENT Misses Survival Endpoint In Earlier TTFields Use
NovoCure's stock fell 19.7% after its Phase 3 TRIDENT trial, testing earlier use of Tumor Treating Fields (TTFields) for glioblastoma, missed its primary overall survival endpoint. While the trial did not show added survival benefit for earlier initiation, it didn't negatively impact survival, suggesting questions around sequencing rather than efficacy. This outcome highlights NovoCure's shifting focus to new indications like pancreatic cancer and the importance of execution in adoption and reimbursement for its broader investment narrative.
NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result
NovoCure (NVCR) shares reacted to topline data from the TRIDENT trial, which showed no improvement in overall survival when starting Tumor Treating Fields therapy during chemoradiation versus later. Despite this, the stock is considered 31.5% undervalued by one narrative, projecting future growth from new indications and market expansion. However, a Discounted Cash Flow model suggests an even larger potential upside, while also noting risks from ongoing losses and reliance on TTFields' relevance.
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks
NovoCure's Phase 3 TRIDENT study for brain cancer did not meet its primary endpoint, showing no statistically significant improvement in overall survival when TTFields therapy was started early alongside chemoradiation versus later during maintenance therapy. Despite the trial's failure to improve overall survival, the safety profile was consistent with prior studies, and long-term survival outcomes remained durable in both groups. The company's stock experienced a significant drop following the announcement, although the FDA recently approved another Novocure therapy, Optune Pax, for pancreatic cancer.
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
SueWallSt has initiated an investigation into Novocure Limited (NASDAQ: NVCR) and its officers and directors after the company's Phase 3 TRIDENT trial failed to meet its primary endpoint, causing shares to drop over 18% on June 18, 2026. This probe follows previous claims by Novocure's CEO about the potential for extended therapy duration and continued growth. Investors who suffered losses are encouraged to contact SueWallSt for a free evaluation of their legal rights.
Novocure device fails to improve brain cancer patients’ survival in phase 3 test
Novocure's tumor-treating electric fields device, Optune Gio, did not meet its primary endpoint in a phase 3 trial for newly diagnosed glioblastoma. The Trident trial aimed to assess the device's effectiveness when initiated at the start of chemoradiation compared to a later maintenance phase, but showed no statistically significant improvement in overall survival. Shares in Novocure fell by nearly 25% following the announcement.
FreeCast surges premarket; Accenture, Novocure slide
FreeCast (NASDAQ:CAST) shares surged after announcing a reseller agreement for Starlink Business services. Conversely, Accenture (NYSE:ACN) tumbled after trimming its annual revenue growth forecast, and Novocure (NASDAQ:NVCR) fell following the failure of its Phase 3 TRIDENT study for glioblastoma. U.S. stock futures generally ticked higher on Thursday due to a Middle East peace deal easing concerns, despite the Federal Reserve's hawkish policy outlook.
Novocure TRIDENT trial misses primary endpoint
Novocure's Phase 3 TRIDENT trial for glioblastoma failed to meet its primary endpoint of improved overall survival, causing a significant decline in the company's stock price. The trial, comparing TTFields therapy initiation timing, showed median overall survival of 17.7 months versus 17.5 months. Despite the outcome, the treatment was well-tolerated with no new safety signals, and Novocure plans further data analysis.
Novocure (NASDAQ: NVCR) Phase 3 TRIDENT glioblastoma study misses survival endpoint
Novocure (NASDAQ: NVCR) announced that its Phase 3 TRIDENT trial, evaluating earlier initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma, did not meet its primary endpoint of overall survival. While early initiation of TTFields therapy was well-tolerated with no new safety signals, the median overall survival was statistically similar between the early start and maintenance start arms. The results highlight the therapy's safety and feasibility with chemoradiation, and will be presented at the ASTRO 2026 Annual Meeting.
Novocure's glioblastoma trial shows survival data, but no primary win
Novocure's Phase 3 TRIDENT trial for newly diagnosed glioblastoma did not meet its primary endpoint of significantly increasing overall survival by initiating Tumor Treating Fields (TTFields) therapy at the start of chemoradiation compared to the maintenance phase. Despite this, the trial demonstrated durable survival benefits in both treatment arms and confirmed the feasibility and safety of early TTFields initiation. Additional analyses are anticipated, which may inform future treatment approaches for specific patient characteristics.
Novocure Ltd (NVCR) Earnings Forecast: Future EPS & Revenue Growth Estimates
Novocure Ltd (NVCR) has an earnings forecast score of 8.00, placing it 66th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $24.00 for NVCR, with forecasts ranging from $14.50 to $42.00, and most analysts recommending a "Buy" trend. The company's expected revenue for the next quarter is $172.72 million, and its EPS for the next quarter is projected at -$0.33.
Novocure Ltd (NVCR) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Novocure Ltd (NVCR), listing its major shareholders and institutional holdings. Key shareholders include Fidelity Management & Research Company LLC, Soleus Capital Management, L.P., and BlackRock Institutional Trust Company, N.A., alongside a breakdown of shareholder types like investment advisors and hedge funds. It also provides a historical overview of institutional shareholding changes and lists related ETFs.
Novocure Shares Slide After Phase 3 Glioblastoma Study Falls Short of Survival Goal
Novocure's shares dropped 10% after its Phase 3 TRIDENT trial, designed to test earlier use of its Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma, failed to meet its primary objective of improving overall survival. The study found no statistically significant improvement when initiating TTFields therapy during chemoradiation compared to later during the maintenance phase. Despite the setback in survival outcomes, the trial confirmed the safety and feasibility of earlier TTFields use, with results slated for presentation at a 2026 oncology conference.
Novocure Ltd (NVCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Novocure Ltd (NVCR) by region. For the reported period, the United States accounted for the largest share of revenue at 58.84%, followed by Germany and France. Information regarding business segments and profit contribution is noted as not yet disclosed by the company.
Novocure Ltd (NVCR) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical data on dividends and stock splits for Novocure Ltd (NVCR), a company listed on Nasdaq, as of June 17, 2024. It indicates that Novocure has not distributed any dividends over the past five years and has no recorded stock split history. The company currently has a market capitalization of $2.07 billion.
NovoCure (NVCR) Appoints Frank Leonard To Its Board After Shareholder Vote
NovoCure (NasdaqGS:NVCR) has appointed Frank Leonard to its board of directors following a shareholder vote at the company's recent annual general meeting. This appointment marks a significant governance event during a critical period for NovoCure, as the company faces mixed stock performance and ongoing challenges related to reimbursement and clinical milestones. Investors will be observing how Leonard contributes to decisions on capital allocation, pipeline focus, and risk management to help navigate the company through its current standing in the market.
NovoCure Ltd stock (JE00B6T5S470): Focus on Tumor Treating Fields technology as investors weigh recent trial data and volatility
NovoCure Ltd continues to draw investor attention due to its Tumor Treating Fields (TTFields) technology, recent pancreas cancer trial data, and volatile share price. Despite positive Phase 2 PANOVA-4 data for metastatic pancreatic cancer, the stock experienced a decline, reflecting the market's sensitivity to clinical and expectation-driven news. The company's future hinges on regulatory decisions, reimbursement success, and translating trial data into sustainable commercial adoption.
Frank Leonard’s Board Appointment and Insider Selling Might Change The Case For Investing In NovoCure (NVCR)
NovoCure shareholders elected Frank Leonard to the board, a change coinciding with questions surrounding recent insider share sales and the stock potentially trading below its estimated intrinsic value. While the company raised its net revenue guidance, concerns about sustained losses and reimbursement uncertainty remain, and the impact of these developments on NovoCure's investment narrative is explored.
Have Insiders Sold NovoCure Shares Recently?
NovoCure's CEO recently sold a significant portion of shares worth US$615k, though another insider made a large purchase at a lower price earlier. Over the past year, insiders have sold more shares than they bought. While the company has high insider ownership, the recent selling trend raises some concerns for investors.
Have Insiders Sold NovoCure Shares Recently?
NovoCure Limited's CEO & Director, Frank Leonard, recently sold shares worth US$615k, reducing his holding by 19%. While there was a significant insider purchase by Ashley Cordova at a lower price point, overall insider sales have outweighed purchases in the last year. Despite high insider ownership, the pattern of recent sales raises some concerns about the stock's attractiveness.
NovoCure (NASDAQ: NVCR) investors OK directors and tight 2024 incentive plan vote
NovoCure Limited's shareholders re-elected eleven directors, ratified their auditor, and approved executive compensation in a non-binding advisory vote at their annual general meeting. A narrowly contested vote also led to the approval of the company's Amended and Restated 2024 Omnibus Incentive Plan. The meeting saw significant shareholder participation, with 81.01% of eligible shares represented.
NovoCure (NVCR) CEO sells 34,273 shares in tax-related transaction
NovoCure Ltd. CEO Leonard Frank X sold 34,273 Ordinary Shares at a weighted average price of $17.9335 per share. This "sell to cover" transaction was mandated to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units and is not considered a discretionary trade. After the sale, the CEO directly holds 459,520 Ordinary Shares.
NovoCure (NASDAQ: NVCR) director granted RSUs and options in new equity awards
NovoCure Ltd director Gabriel Leung was granted new equity awards, including 11,610 Ordinary Shares as restricted stock units and stock options for 16,999 Ordinary Shares at an exercise price of $16.15. These awards bring his direct holdings to 101,109 Ordinary Shares. Both the RSUs and options are scheduled to vest 100% on the earlier of one year from the June 3, 2026 grant date or the day before NovoCure's 2027 annual general meeting of shareholders.
NovoCure (NVCR) director receives new share and stock option awards
NovoCure Ltd director Allyson J. Ocean was granted 11,610 restricted stock units and stock options for 16,999 ordinary shares. The restricted stock units and stock options will vest 100% on the earlier of the first anniversary of the grant or the day preceding the company’s 2027 annual general meeting. Following these awards, Ocean directly holds 22,934 ordinary shares, with the stock options having an exercise price of $16.15 per share and expiring on June 3, 2036.
NovoCure (NASDAQ: NVCR) director granted RSUs and options in 2026 award
NovoCure Ltd director Kristin Stafford was granted new equity awards on June 3, 2026, including 11,610 restricted stock units and stock options for 16,999 ordinary shares with an exercise price of $16.15. These awards are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day before NovoCure's 2027 annual general meeting. Following these grants, Stafford directly holds 22,934 ordinary shares and 16,999 stock options.
